Investigational drug · Phase 2
BioTTT001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent High-grade Glioma.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "BioTTT001"
First trial start
2024
Nov 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BioTTT001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent High-grade Glioma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BioTTT001" as an intervention, largest first.
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruiting
China Medical University, ChinaAcademic, hospital or other
NCT06283134 · 60 participants (planned) · Start Mar 2026 · Primary completion Dec 1, 2027
Drug: BioTTT001 hepatic artery infusion; toripalimab and 1 more · For: Colorectal Cancer Metastatic
Henan Cancer HospitalGovernment (non-federal)
NCT07264569 · 42 participants (planned) · Start Jun 25, 2025 · Primary completion Dec 30, 2027
Drug: BioTTT001 injection · For: Meningeal Metastasis
Sites: Zhengzhou, China
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric CancerNot yet recruiting
China Medical University, ChinaAcademic, hospital or other
NCT06283121 · 30 participants (planned) · Start Apr 2, 2024 · Primary completion Nov 30, 2027
Drug: BioTTT001 intraperitoneal infusion; SOX regimen and 1 more · For: Gastric Cancer, Metastatic
- Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.Enrolling by invitation
Beijing Bio-Targeting Therapeutics Technology Co., LtdIndustry
NCT06763965 · 30 participants (planned) · Start Nov 26, 2024 · Primary completion Jul 31, 2027
Drug: BioTTT001 injection · For: Recurrent High-grade Glioma
Sites: Beijing, China
- A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade GliomaNot yet recruiting
Beijing Bio-Targeting Therapeutics Technology Co., LtdIndustry
NCT07472790 · 15 participants (planned) · Start Jul 31, 2026 · Primary completion Apr 30, 2028
Drug: Novel oncolytic virus Ad-TD-nsIL12(BioTTT001) · For: High-grade Glioma
Sites: Beijing, China
- A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid TumorsEnrolling by invitation
Beijing Bio-Targeting Therapeutics Technology Co., LtdIndustry
NCT06215846 · 12 participants (planned) · Start May 7, 2024 · Primary completion May 30, 2026
Drug: BioTTT001 injection · For: Solid Tumor
Sites: Shenyang, China
Beijing Bio-Targeting Therapeutics Technology Co., LtdIndustry
NCT07150767 · 0 participants · Start Mar 26, 2025 · Primary completion Mar 26, 2027
Drug: BioTTT001 injection · For: Locally Advanced Breast Cancer (LABC)
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.